Avanos Medical Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Avanos Medical has an operating margin of -57.6%, meaning the company retains $-58 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from 0.6% the prior year.
Avanos Medical's revenue grew a modest 2.2% year-over-year to $687.8M. This slow but positive growth earns a score of 35/100.
Avanos Medical carries a low D/E ratio of 0.15, meaning only $0.15 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.37, Avanos Medical holds $2.37 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 75/100.
Avanos Medical has a free cash flow margin of 12.0%, earning a moderate score of 60/100. The company generates positive cash flow after capital investments, but with room for improvement.
Avanos Medical passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Avanos Medical generates $-0.26 in operating cash flow ($100.7M OCF vs -$392.1M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Avanos Medical earns $-32.5 in operating income for every $1 of interest expense (-$396.2M vs $12.2M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Avanos Medical (AVNS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Avanos Medical generated $687.8M in revenue in fiscal year 2024. This represents an increase of 2.2% from the prior year.
Avanos Medical's EBITDA was -$350.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 797.2% from the prior year.
Avanos Medical generated $82.9M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 467.8% from the prior year.
Avanos Medical reported -$392.1M in net income in fiscal year 2024. This represents a decrease of 534.5% from the prior year.
Avanos Medical earned $-8.53 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 546.2% from the prior year.
Avanos Medical held $107.7M in cash against $125.3M in long-term debt as of fiscal year 2024.
Avanos Medical had 46M shares outstanding in fiscal year 2024. This represents a decrease of 0.5% from the prior year.
Avanos Medical's gross margin was 55.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 0.9 percentage points from the prior year.
Avanos Medical's operating margin was -57.6% in fiscal year 2024, reflecting core business profitability. This is down 58.2 percentage points from the prior year.
Avanos Medical's net profit margin was -57.0% in fiscal year 2024, showing the share of revenue converted to profit. This is down 47.8 percentage points from the prior year.
Avanos Medical invested $26.2M in research and development in fiscal year 2024. This represents a decrease of 3.7% from the prior year.
Avanos Medical spent $12.8M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 33.0% from the prior year.
Avanos Medical invested $17.8M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 0.0% from the prior year.
AVNS Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $177.8M+1.6% | $175.0M+4.5% | $167.5M-6.7% | $179.6M+4.6% | $171.7M+3.4% | $166.1M-4.2% | $173.3M+1.2% | $171.3M |
| Cost of Revenue | $91.8M+10.7% | $82.9M+6.7% | $77.7M-4.8% | $81.6M+7.2% | $76.1M+6.7% | $71.3M-8.9% | $78.3M+3.3% | $75.8M |
| Gross Profit | $86.0M-6.6% | $92.1M+2.6% | $89.8M-8.4% | $98.0M+2.5% | $95.6M+0.8% | $94.8M-0.2% | $95.0M-0.5% | $95.5M |
| R&D Expenses | $6.0M+3.4% | $5.8M+7.4% | $5.4M-5.3% | $5.7M-9.5% | $6.3M-10.0% | $7.0M+2.9% | $6.8M+11.5% | $6.1M |
| SG&A Expenses | $77.6M-7.1% | $83.5M+10.3% | $75.7M-5.0% | $79.7M-1.5% | $80.9M-3.2% | $83.6M+12.2% | $74.5M-5.3% | $78.7M |
| Operating Income | $100K+100.1% | -$74.5M-823.3% | $10.3M+102.5% | -$418.5M-6742.9% | $6.3M+57.5% | $4.0M-64.3% | $11.2M+833.3% | $1.2M |
| Interest Expense | $1.8M-10.0% | $2.0M-4.8% | $2.1M-25.0% | $2.8M-9.7% | $3.1M0.0% | $3.1M-6.1% | $3.3M-29.8% | $4.7M |
| Income Tax | $200K-77.8% | $900K-71.0% | $3.1M+113.2% | -$23.5M-1336.8% | $1.9M+90.0% | $1.0M+147.6% | -$2.1M-133.9% | $6.2M |
| Net Income | -$1.4M+98.2% | -$76.8M-1263.6% | $6.6M+101.7% | -$397.3M-22172.2% | $1.8M+300.0% | -$900K-108.6% | $10.5M+383.8% | -$3.7M |
| EPS (Diluted) | $-0.03+98.2% | $-1.66-1285.7% | $0.14+101.6% | $-8.64-21700.0% | $0.04+300.0% | $-0.02-108.7% | $0.23+387.5% | $-0.08 |
AVNS Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.1B+2.8% | $1.0B-6.2% | $1.1B-4.0% | $1.2B-30.4% | $1.7B-0.2% | $1.7B-1.8% | $1.7B-1.9% | $1.7B |
| Current Assets | $351.4M-1.3% | $356.0M+1.0% | $352.4M-10.4% | $393.4M-17.0% | $474.1M+1.3% | $467.8M-3.9% | $487.0M-7.2% | $524.6M |
| Cash & Equivalents | $70.5M-21.9% | $90.3M-6.9% | $97.0M-9.9% | $107.7M+16.8% | $92.2M+21.6% | $75.8M-13.6% | $87.7M-18.1% | $107.1M |
| Inventory | $150.6M+5.5% | $142.7M+3.3% | $138.1M-0.5% | $138.8M-15.3% | $163.9M-1.0% | $165.6M+1.5% | $163.2M+4.2% | $156.6M |
| Accounts Receivable | $111.5M+1.2% | $110.2M+5.2% | $104.8M-21.1% | $132.8M+8.0% | $123.0M-6.3% | $131.3M-8.1% | $142.8M-1.7% | $145.2M |
| Goodwill | $394.4M+3.5% | $381.2M-16.4% | $455.9M+0.1% | $455.6M-42.6% | $794.4M-0.1% | $794.9M-0.2% | $796.1M+0.6% | $791.5M |
| Total Liabilities | $289.7M+10.3% | $262.7M-2.1% | $268.4M-17.6% | $325.7M-25.3% | $435.8M+0.6% | $433.4M-5.0% | $456.1M-9.3% | $502.8M |
| Current Liabilities | $147.9M+9.9% | $134.6M-1.9% | $137.2M-17.3% | $165.9M-20.3% | $208.2M+1.5% | $205.2M-12.5% | $234.6M+37.4% | $170.7M |
| Long-Term Debt | $93.4M-2.4% | $95.7M-2.3% | $98.0M-21.8% | $125.3M-24.0% | $164.9M-1.4% | $167.2M+4.9% | $159.4M-38.3% | $258.3M |
| Total Equity | $778.0M+0.2% | $776.3M-7.5% | $839.4M+1.3% | $828.5M-32.2% | $1.2B-0.5% | $1.2B-0.7% | $1.2B+1.2% | $1.2B |
| Retained Earnings | -$778.6M-0.2% | -$777.2M-11.0% | -$700.4M+0.9% | -$707.0M-125.2% | -$314.0M+0.6% | -$315.8M-0.3% | -$314.9M+3.2% | -$325.4M |
AVNS Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $14.0M+105.9% | $6.8M-73.5% | $25.7M-55.6% | $57.9M+108.3% | $27.8M+447.5% | -$8.0M-163.0% | $12.7M-56.4% | $29.1M |
| Capital Expenditures | $7.0M-36.4% | $11.0M+64.2% | $6.7M+39.6% | $4.8M-18.6% | $5.9M+43.9% | $4.1M-30.5% | $5.9M+51.3% | $3.9M |
| Free Cash Flow | $7.0M+266.7% | -$4.2M-122.1% | $19.0M-64.2% | $53.1M+142.5% | $21.9M+281.0% | -$12.1M-277.9% | $6.8M-73.0% | $25.2M |
| Investing Cash Flow | -$31.5M-138.6% | -$13.2M-45.1% | -$9.1M-19.7% | -$7.6M-28.8% | -$5.9M-195.0% | -$2.0M-102.5% | $81.0M+265.6% | -$48.9M |
| Financing Cash Flow | -$2.0M+37.5% | -$3.2M+89.0% | -$29.1M-6.2% | -$27.4M-448.0% | -$5.0M-614.3% | -$700K+99.4% | -$114.7M-345.6% | $46.7M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0-100.0% | $800K-63.6% | $2.2M+2100.0% | $100K-97.1% | $3.5M-61.5% | $9.1M+46.8% | $6.2M-32.6% | $9.2M |
AVNS Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 48.4%-4.3pp | 52.6%-1.0pp | 53.6%-1.0pp | 54.6%-1.1pp | 55.7%-1.4pp | 57.1%+2.2pp | 54.8%-0.9pp | 55.8% |
| Operating Margin | 0.1%+42.6pp | -42.6%-48.7pp | 6.2%+239.2pp | -233.0%-236.7pp | 3.7%+1.3pp | 2.4%-4.1pp | 6.5%+5.8pp | 0.7% |
| Net Margin | -0.8%+43.1pp | -43.9%-47.8pp | 3.9%+225.2pp | -221.2%-222.3pp | 1.1%+1.6pp | -0.5%-6.6pp | 6.1%+8.2pp | -2.2% |
| Return on Equity | N/A | N/A | 0.8%+0.4pp | 0.4%+0.2pp | 0.1% | N/A | 0.9% | N/A |
| Return on Assets | -0.1%+7.3pp | -7.4%-8.0pp | 0.6%+35.0pp | -34.4%-34.5pp | 0.1%+0.2pp | -0.1%-0.7pp | 0.6%+0.8pp | -0.2% |
| Current Ratio | 2.38-0.3 | 2.64+0.1 | 2.57+0.2 | 2.37+0.1 | 2.280.0 | 2.28+0.2 | 2.08-1.0 | 3.07 |
| Debt-to-Equity | 0.120.0 | 0.120.0 | 0.12-0.0 | 0.15+0.0 | 0.130.0 | 0.140.0 | 0.13-0.1 | 0.21 |
| FCF Margin | 3.9%+6.3pp | -2.4%-13.7pp | 11.3%-18.2pp | 29.6%+16.8pp | 12.8%+20.0pp | -7.3%-11.2pp | 3.9%-10.8pp | 14.7% |
Similar Companies
Frequently Asked Questions
What is Avanos Medical's annual revenue?
Avanos Medical (AVNS) reported $687.8M in total revenue for fiscal year 2024. This represents a 2.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Avanos Medical's revenue growing?
Avanos Medical (AVNS) revenue grew by 2.2% year-over-year, from $673.3M to $687.8M in fiscal year 2024.
Is Avanos Medical profitable?
No, Avanos Medical (AVNS) reported a net income of -$392.1M in fiscal year 2024, with a net profit margin of -57.0%.
What is Avanos Medical's earnings per share (EPS)?
Avanos Medical (AVNS) reported diluted earnings per share of $-8.53 for fiscal year 2024. This represents a -546.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Avanos Medical's EBITDA?
Avanos Medical (AVNS) had EBITDA of -$350.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Avanos Medical have?
As of fiscal year 2024, Avanos Medical (AVNS) had $107.7M in cash and equivalents against $125.3M in long-term debt.
What is Avanos Medical's gross margin?
Avanos Medical (AVNS) had a gross margin of 55.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Avanos Medical's operating margin?
Avanos Medical (AVNS) had an operating margin of -57.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Avanos Medical's net profit margin?
Avanos Medical (AVNS) had a net profit margin of -57.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Avanos Medical's free cash flow?
Avanos Medical (AVNS) generated $82.9M in free cash flow during fiscal year 2024. This represents a 467.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Avanos Medical's operating cash flow?
Avanos Medical (AVNS) generated $100.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Avanos Medical's total assets?
Avanos Medical (AVNS) had $1.2B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Avanos Medical's capital expenditures?
Avanos Medical (AVNS) invested $17.8M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Avanos Medical spend on research and development?
Avanos Medical (AVNS) invested $26.2M in research and development during fiscal year 2024.
Does Avanos Medical buy back shares?
Yes, Avanos Medical (AVNS) spent $12.8M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Avanos Medical have outstanding?
Avanos Medical (AVNS) had 46M shares outstanding as of fiscal year 2024.
What is Avanos Medical's current ratio?
Avanos Medical (AVNS) had a current ratio of 2.37 as of fiscal year 2024, which is generally considered healthy.
What is Avanos Medical's debt-to-equity ratio?
Avanos Medical (AVNS) had a debt-to-equity ratio of 0.15 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Avanos Medical's return on assets (ROA)?
Avanos Medical (AVNS) had a return on assets of -34.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Avanos Medical's Piotroski F-Score?
Avanos Medical (AVNS) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Avanos Medical's earnings high quality?
Avanos Medical (AVNS) has an earnings quality ratio of -0.26x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Avanos Medical cover its interest payments?
Avanos Medical (AVNS) has an interest coverage ratio of -32.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Avanos Medical?
Avanos Medical (AVNS) scores 54 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.